XIN LI

TitlePostdoc Fellows and Associates
InstitutionBaylor College of Medicine
DepartmentPostDoc
Address
Email
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Aliases
    Collapse Verify Publications

    Collapse Overview 
    Collapse overview
    Postdoctoral Research Associate at Baylor College of Medicine with expertise in Medicinal Chemistry and Drug Discovery

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Li X, Song Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol. 2020 05 13; 13(1):50. PMID: 32404196.
      Citations:    Fields:    
    2. Wang W, Qin JJ, Rajaei M, Li X, Yu X, Hunt C, Zhang R. Targeting MDM2 for novel molecular therapy: Beyond oncology. Med Res Rev. 2020 May; 40(3):856-880. PMID: 31587329.
      Citations: 5     Fields:    
    3. Wang W, Hu B, Qin JJ, Cheng JW, Li X, Rajaei M, Fan J, Yang XR, Zhang R. A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance. Genes Dis. 2019 Dec; 6(4):419-430. PMID: 31832522.
      Citations:    
    4. Wang W, Cheng JW, Qin JJ, Hu B, Li X, Nijampatnam B, Velu SE, Fan J, Yang XR, Zhang R. MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53. Cancer Lett. 2019 09 10; 459:156-167. PMID: 31181320.
      Citations: 5     Fields:    Translation:HumansCells
    5. Wang W, Qin JJ, Li X, Tao G, Wang Q, Wu X, Zhou J, Zi X, Zhang R. Prevention of prostate cancer by natural product MDM2 inhibitor GS25: in vitro and in vivo activities and molecular mechanisms. Carcinogenesis. 2018 07 30; 39(8):1026-1036. PMID: 29762656.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    6. Qin JJ, Li X, Hunt C, Wang W, Wang H, Zhang R. Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine. Genes Dis. 2018 Sep; 5(3):204-219. PMID: 30320185.
      Citations:    
    7. Qin JJ, Wang W, Li X, Deokar H, Buolamwini JK, Zhang R. Inhibiting ß-Catenin by ß-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Front Pharmacol. 2018; 9:5. PMID: 29387014.
      Citations:    
    8. Qin JJ, Li X, Wang W, Zi X, Zhang R. Targeting the NFAT1-MDM2-MDMX Network Inhibits the Proliferation and Invasion of Prostate Cancer Cells, Independent of p53 and Androgen. Front Pharmacol. 2017; 8:917. PMID: 29311926.
      Citations:    
    9. Qiang S, Wang C, Venter H, Li X, Wang Y, Guo L, Ma R, Ma S. Synthesis and Biological Evaluation of Novel FtsZ-targeted 3-arylalkoxy-2,6-difluorobenzamides as Potential Antimicrobial Agents. Chem Biol Drug Des. 2016 Feb; 87(2):257-64. PMID: 26348110.
      Citations: 2     Fields:    Translation:Cells
    10. Yan M, Ma X, Dong R, Li X, Zhao C, Guo Z, Shen Y, Liu F, Ma R, Ma S. Synthesis and antibacterial activity of 4?-O-(trans-ß-arylacrylamido)carbamoyl azithromycin analogs. Eur J Med Chem. 2015 Oct 20; 103:506-15. PMID: 26402728.
      Citations:    Fields:    Translation:Cells
    11. Li X, Sheng J, Huang G, Ma R, Yin F, Song D, Zhao C, Ma S. Design, synthesis and antibacterial activity of cinnamaldehyde derivatives as inhibitors of the bacterial cell division protein FtsZ. Eur J Med Chem. 2015 Jun 05; 97:32-41. PMID: 25938986.
      Citations: 4     Fields:    Translation:Cells
    12. Li X, Ma S. Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ. Eur J Med Chem. 2015 May 05; 95:1-15. PMID: 25791674.
      Citations: 11     Fields:    Translation:Cells
    13. Li X, Ma S. Recent developments in the discovery of novel antipsychotic agents modualating dopamine and serotonin receptors. Curr Drug Targets. 2013 Jul; 14(8):899-918. PMID: 23701299.
      Citations:    Fields:    Translation:HumansAnimals
    14. Li X, Ma S, Yan M, Wang Y, Ma S. Synthesis and antibacterial evaluation of novel 11,4?-disubstituted azithromycin analogs with greatly improved activity against erythromycin-resistant bacteria. Eur J Med Chem. 2013 Jan; 59:209-17. PMID: 23229056.
      Citations: 1     Fields:    Translation:Cells
    15. Cui W, An L, Ma C, Ma S, Cong C, Li X, Ma S. WITHDRAWN: Novel azithromycin derivatives with the C-4? bisamide side chains: synthesis and biological evaluation against gram-positive bacteria. J Antibiot (Tokyo). 2012 Feb 15. PMID: 22334238.
      Citations:    Fields:    
    16. Cong C, Wang H, Hu Y, Liu C, Ma S, Li X, Cao J, Ma S. Synthesis and antibacterial activity of novel 4?-O-benzimidazolyl clarithromycin derivatives. Eur J Med Chem. 2011 Jul; 46(7):3105-11. PMID: 21524827.
      Citations:    Fields:    Translation:Cells
    LI's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (68)
    Explore
    _
    Co-Authors (1)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _